Puma Biotechnology
PBYI
82 hedge funds and large institutions have $115M invested in Puma Biotechnology in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 29 increasing their positions, 15 reducing their positions, and 6 closing their positions.
287% more call options, than puts
Call options by funds: $843K | Put options by funds: $218K
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
93% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 15
70% more capital invested
Capital invested by funds: $67.6M → $115M (+$47.6M)
19% more funds holding
Funds holding: 69 → 82 (+13)
1.83% more ownership
Funds ownership: 54.1% → 55.94% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.62M |
| 2 |
Man Group
London,
United Kingdom
|
+$559K |
| 3 |
Jane Street
New York
|
+$456K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$445K |
| 5 |
LCM
Laurion Capital Management
New York
|
+$435K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$4.74M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$1.25M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$193K |
| 4 |
Renaissance Technologies
New York
|
-$177K |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$112K |
PBYI Hedge Fund Activity: Q4 2023 in Review
82 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q4 2023, worth a combined $115M — up 70% from $67.6M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new PBYI positions and 6 closed out — a net gain of 13 holders — while 29 added to existing stakes and 15 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $3.62M. The largest seller was Camber Capital Management, cutting an estimated $4.74M.
- 82 institutional investors held Puma Biotechnology (PBYI) as of Q4 2023, up from 69 in Q3 2023.
- Funds reported $115M of Puma Biotechnology stock for Q4 2023, up 70% quarter-over-quarter.
- 19 funds opened new Puma Biotechnology positions in Q4 2023 and 6 closed out, a net change of +13 holders.
- The largest Puma Biotechnology buyer in Q4 2023 was Great Point Partners, an estimated $3.62M added.
- The largest Puma Biotechnology seller in Q4 2023 was Camber Capital Management, an estimated $4.74M sold.
Based on aggregated 13F filings for Q4 2023.